AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,492,883 | +0.2% | 2,178,691 | +3.5% | 0.01% | 0.0% |
| Q2 2023 | $26,451,574 | +15.4% | 2,106,017 | +1.9% | 0.01% | +14.3% |
| Q1 2023 | $22,913,692 | -9.1% | 2,066,158 | +0.0% | 0.01% | -12.5% |
| Q4 2022 | $25,215,884 | +19.5% | 2,065,183 | +2.2% | 0.01% | 0.0% |
| Q3 2022 | $21,096,000 | -1.2% | 2,020,665 | +1.6% | 0.01% | +14.3% |
| Q2 2022 | $21,353,000 | +12.5% | 1,988,136 | -0.8% | 0.01% | +16.7% |
| Q1 2022 | $18,985,000 | -16.0% | 2,004,734 | +2.4% | 0.01% | -14.3% |
| Q4 2021 | $22,611,000 | +26.5% | 1,957,617 | +4.6% | 0.01% | +16.7% |
| Q3 2021 | $17,868,000 | -10.8% | 1,870,933 | -10.0% | 0.01% | -14.3% |
| Q2 2021 | $20,037,000 | +0.4% | 2,078,504 | +2.9% | 0.01% | 0.0% |
| Q1 2021 | $19,963,000 | -54.4% | 2,020,527 | +6.5% | 0.01% | -58.8% |
| Q4 2020 | $43,825,000 | +63.9% | 1,897,967 | +0.2% | 0.02% | +41.7% |
| Q3 2020 | $26,735,000 | -7.8% | 1,893,389 | -1.5% | 0.01% | -14.3% |
| Q2 2020 | $29,002,000 | +70.7% | 1,923,167 | +4.6% | 0.01% | +40.0% |
| Q1 2020 | $16,993,000 | +5.7% | 1,838,992 | +11.4% | 0.01% | +11.1% |
| Q4 2019 | $16,079,000 | +29.9% | 1,650,776 | +6.9% | 0.01% | +28.6% |
| Q3 2019 | $12,380,000 | -31.3% | 1,543,566 | +6.9% | 0.01% | -36.4% |
| Q2 2019 | $18,014,000 | +11.2% | 1,443,427 | +21.1% | 0.01% | +10.0% |
| Q1 2019 | $16,206,000 | +62.4% | 1,191,573 | +14.4% | 0.01% | +25.0% |
| Q4 2018 | $9,977,000 | -20.3% | 1,041,361 | +0.6% | 0.01% | 0.0% |
| Q3 2018 | $12,513,000 | -19.0% | 1,034,905 | +4.6% | 0.01% | -27.3% |
| Q2 2018 | $15,449,000 | +12.7% | 989,006 | +8.5% | 0.01% | 0.0% |
| Q1 2018 | $13,711,000 | +24.7% | 911,618 | +19.4% | 0.01% | +22.2% |
| Q4 2017 | $10,991,000 | -0.4% | 763,775 | +4.4% | 0.01% | -10.0% |
| Q3 2017 | $11,037,000 | +84.8% | 731,875 | +23.4% | 0.01% | +66.7% |
| Q2 2017 | $5,971,000 | +48.8% | 592,934 | +5.3% | 0.01% | +50.0% |
| Q1 2017 | $4,014,000 | +51.6% | 562,951 | +5.7% | 0.00% | +33.3% |
| Q4 2016 | $2,648,000 | -29.2% | 532,774 | +5.5% | 0.00% | -25.0% |
| Q3 2016 | $3,738,000 | +48.9% | 505,081 | +9.8% | 0.00% | +33.3% |
| Q2 2016 | $2,511,000 | -27.7% | 459,801 | +11.8% | 0.00% | -40.0% |
| Q1 2016 | $3,474,000 | -2.6% | 411,111 | +11.8% | 0.01% | 0.0% |
| Q4 2015 | $3,567,000 | -26.8% | 367,696 | +5.6% | 0.01% | -28.6% |
| Q3 2015 | $4,871,000 | +125.4% | 348,106 | +128.0% | 0.01% | +133.3% |
| Q2 2015 | $2,161,000 | +1331.1% | 152,704 | +1006.6% | 0.00% | – |
| Q1 2015 | $151,000 | +31.3% | 13,800 | 0.0% | 0.00% | – |
| Q4 2014 | $115,000 | +38.6% | 13,800 | 0.0% | 0.00% | – |
| Q3 2014 | $83,000 | +76.6% | 13,800 | 0.0% | 0.00% | – |
| Q2 2014 | $47,000 | -59.1% | 13,800 | -75.0% | 0.00% | – |
| Q1 2014 | $115,000 | -11.5% | 55,200 | 0.0% | 0.00% | – |
| Q4 2013 | $130,000 | -0.8% | 55,200 | 0.0% | 0.00% | – |
| Q3 2013 | $131,000 | 0.0% | 55,200 | 0.0% | 0.00% | – |
| Q2 2013 | $131,000 | – | 55,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |